Skip to main content
Quest Diagnostics

Validation and adoption of an IGVH mutational status assay in chronic lymphocytic leukemia (CLL) using next-generation sequencing (NGS) in a clinical laboratory

Association for Molecular Pathology Annual Meeting
AMP 2022

Phoenix, AZ, Nov  1 - 5, 2022

Poster presentation: Validation and adoption of an IGVH mutational status assay in chronic lymphocytic leukemia (CLL) using next-generation sequencing (NGS) in a clinical laboratory

Authors: Prathapam R, Lemoine BF, Dai X, Freitas TAK, Khadgi S, Graham JA, Tan Z, Sun G, Pugh BS, Marmolejo IA, Shahbahrami B, Cacho DM, Ngo DQ, Ma CK, Champion KJ

Specialties: Genetics, Oncology

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.